Rabasseda X
Medical Information & Documentation Department, Prous Science, Barcelona, Spain.
Drugs Today (Barc). 1998 Nov;34(11):905-26. doi: 10.1358/dot.1998.34.11.487475.
Carvedilol is a multiple-action drug with alpha(1)- and beta-adrenergic receptor antagonistic, calcium channel blocker and antioxidant activities especially useful in the treatment of hypertension. The antioxidant activity of the drug depends on the carbazole moiety, which is unique to carvedilol and is also present in some of the metabolites lacking either the alpha(1)- or beta-adrenergic receptor blocking activity. These antioxidant properties account for the exceptional ability of carvedilol to reduce cardiac necrosis in animal models of myocardial infarction, as well as its neuroprotective activities in in vivo and in vitro models of brain ischemia. A further property of carvedilol is its ability to inhibit vascular smooth muscle cell migration and proliferation, and neointima formation, after vascular injuries. The identification of all these activities of carvedilol indicates that it is a singular multiple-action antihypertensive agent with potential for cardiovascular organ protection beyond the normalization of high blood pressure.
卡维地洛是一种具有多种作用的药物,具有α₁和β肾上腺素能受体拮抗、钙通道阻滞及抗氧化活性,尤其适用于高血压治疗。该药物的抗氧化活性取决于咔唑部分,这是卡维地洛所特有的,并且在一些缺乏α₁或β肾上腺素能受体阻断活性的代谢产物中也存在。这些抗氧化特性解释了卡维地洛在心肌梗死动物模型中减少心肌坏死的卓越能力,以及其在脑缺血体内和体外模型中的神经保护活性。卡维地洛的另一个特性是其在血管损伤后抑制血管平滑肌细胞迁移、增殖及新内膜形成的能力。卡维地洛所有这些活性的发现表明,它是一种独特的多作用抗高血压药物,除了使高血压正常化之外,还具有心血管器官保护潜力。